Profil
Brian Cathers worked as an Executive Director-Protein Homeostasis at Celgene Corp.
from 2015 to 2019.
He also worked as a Chief Scientific Officer at Global Blood Therapeutics, Inc. Dr. Cathers completed his undergraduate degree at Emporia State University and his graduate and doctorate degrees at the University of Kansas.
Anciens postes connus de Brian Cathers
| Sociétés | Poste | Fin |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 01/02/2019 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Brian Cathers
| Emporia State University | Undergraduate Degree |
| University of Kansas | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
